Pegasys and Copegus for Asian patients with treatment-naive hepatitis C genotypes 6, 7, 8, 9: a phase IV, randomized, open-labeled, multicenter trial comparing 24-week vs. 48-week therapy.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Dec 2009 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jan 2008 New trial record.